Año 2022 / Volumen 114 / Número 12
Editorial
Drug induced liver injury by immunotherapy

705-707

DOI: 10.17235/reed.2022.9179/2022

Einar Stefan Björnsson,

Resumen
Immunotherapy has become the cornerstone of treatment of many malignancies. Check point inhibitors (CPIs) have been shown to be able to halt the progression of several types of advanced malignancies such as malignant melanoma and even keep patients in longstanding clinical remission (1-2). Thus, the use of CPIs has shown a substantial therapeutic benefit marked by signficant improvement in patient survival. However, this efficacy comes with a cost of several immune associated adverse effects due to the corollary reduction of immune self-tolerance. These adverse can be manifested as gastrointestinal symptoms (colitis), dermatological (dermatitis), lung symptoms (pneumonitis), endocrine manifestations (hypophysitis), apart from drug-induced liver injury (DILI), which is the focus of this editorial. Among 100 DILI patients due to CPIs of whom 53% had advanced melanoma, 45% had concomitant immune-mediated adverse effects, with dermatological (14%) and colitis (9%) being the most common (3).
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Haanen J, Robert C. Immune Checkpoint Inhibitors. Prog Tumor Res 2015; 42: 55-66. DOI: 10.1159/000437178
2. Pennock GK, Chowb LQM. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. The Oncologist 2015; 20: 812–822.
3. Miller ED, Abu-Sbeih H, Styskel B, Gonzalez GMN, Blechacz B, Naing A, Chalasani N. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. Am. J. Gastroenterol 2020; 115: 251-261. DOI: 10.14309/ajg.0000000000000398
4. Shah P, Sundaram, V., and Bjornsson ES. Biologic and Checkpoint Inhibitor-Induced. Liver Injury: A Systematic Literature Review. Hepatol. Commun 2020; 4: 172-184. DOI: 10.1002/hep4.1465
5. Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018; 38: 976-87.
6. Hoofnagle JH, Bjornsson ES. Drug Induced Liver Injury: Types and Phenotypes. New Engl J Med 2019; 381, 264-273. DOI: 10.1056/NEJMra1816149
7. Riveiro-Barciela M, Barreira-Díaz A, Vidal-González J, Muñoz-Couselo E, Martínez-Valle F, Viladomiu L, Mínguez B, Ortiz-Velez C, Castells L, Esteban R, Buti M. Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. Liver Int 2020; 40: 1906-1916. DOI: 10.1111/liv.14489
8. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Ann. Oncol 2018; 29: iv264-iv266.
9. Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M.,et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768.
10. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 2017; 5: 1-28.
11. Cohen JV, Dougan M, Zubiri L, Reynolds KL, Sullivan RJ, Misdraji J. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol. 2021 Feb;34(2):426-437.
12. Ogawa K, Kamimura K, Terai S. Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis. Hepatology 2019; 69: 914-916.
13. Nabeshima S, Yamasaki M, Matsumoto N, Takaki S, Nishi Y, Kawamoto K, et al. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report. Cancer Treat Res Commun 2021; 26: 100270.
14. De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018:68:1181-90.
15. Gauci ML, Baroudjian B, Zeboulon C, Pages C, Poté N, Roux O, et al. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed? J. Hepatol 2018; 69: 548-550.
16. Björnsson ES, Vucic V, Stirnimann G, Robles-Díaz M. Role of corticosteroids in Drug-induced liver injury. A systematic review. Front Pharmacol. 2022 Feb 10;13:820724.
17. Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, J Cohen J 1, Ryan J Sullivan. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 2018; 15; 124: 3706-3714.
18. Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015; 21: 749-55.
19. Castillo MD, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clin Infect Dis. 2016; 63:1490–1493.
20. Li M, Wong D, Vogel AS, Sack JS, Rahma OS, Hodi FS, Zucker SD, Grover S. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology 2022; 75: 531-540.
Artículos relacionados

Carta

Daño hepatocelular inducido por doxazosina

DOI: 10.17235/reed.2020.7268/2020

Carta

Hepatitis aguda por olmesartán: una entidad infrecuente

DOI: 10.17235/reed.2020.7236/2020

Instrucciones para citar
Björnsson E. Drug induced liver injury by immunotherapy . 9179/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 880 veces.
Este artículo ha sido descargado 140 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 02/09/2022

Aceptado: 02/09/2022

Prepublicado: 23/09/2022

Publicado: 12/12/2022

Tiempo de prepublicación: 21 días

Tiempo de edición del artículo: 101 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas